Chemical industry – Page 74
-
Business
Indian manufacturers hit back over quality claims
Study showing drugs exported to Africa are substandard prompts backlash from generic drugmakers
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
Business
Bio-based chemicals on the rise in US
Government predicts 10% of chemicals market will be renewable by 2015
-
Business
Endo outbids QLT for Auxilium merger
Biotech backs out of Canadian deal in favour of increased $2.6bn bid from Endo
-
Business
EMA finalises trial transparency rules
Researcher access reinstated, but company redaction rights may cause issues
-
Business
US tax changes ripple into merger deals
Efforts to curb tax-avoiding ‘inversion’ deals will slow, but not stop, the wave
-
Business
Actavis boosts antibiotics with Durata buyout
$820 million deal gives Actavis control of newly-approved intravenous antibiotic
-
Business
Becton Dickinson to buy CareFusion for $12bn
Medical devices merger continues consolidation trend
-
Business
J&J to buy antiviral specialist Alios
$1.75 billion deal brings Phase II compounds for hepatitis C and respiratory syncytial virus
-
Business
Dow’s $1bn price-fixing fine upheld
Firm loses its appeal against damages for fixing polyurethane prices
-
Feature
Transparency measures forced on pharma
Previous misdemeanours are compelling the pharmaceutical industry to be more open with financial information and clinical data, writes Nuala Moran
-
Business
Mitsubishi to buy Japanese gases specialist
Taiyo Nippon Sanso acquisition continues consolidation in Japan’s chemical industry
-
Business
Lumara splits and sells to AMAG and Perrigo
Lumara has just emerged from bankruptcy and brings a drug for suppressing pre-term birth, plus other women’s health products
-
Business
Merck KGaA to buy Sigma–Aldrich
$17bn acquisition expands Merck’s life science business and US presence, but it isn’t stepping back from drug development
-
Business
India backs off drug pricing controls
Current price caps will stand, but rules on how new caps can be imposed are being tightened
-
Business
Review says cheaper drug is safe for eye disease
Cochrane collaboration says side effects of expensive Lucentis and off-label Avastin are similar
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
Business
Bayer to sever polymer arm
German chemical giant’s exit from the materials world will help fund its crop and healthcare ambitions
-
Business
US drops restrictions on more GM seeds
Dow’s herbicide-resistant corn and soybeans spark renewed criticism from environmental campaigners